Shin Egawa - Search Results

Year	Number of Results
2002	10
2003	7
2004	2
2005	11
2006	10
2007	4
2008	13
2009	16
2010	6
2011	13
2012	16
2013	14
2014	16
2015	17
2016	20
2017	13
2018	23
2019	35
2020	57
2021	67
2022	52
2023	13
2024	2

1

Cytoplasmic Androgen Receptor, CD24 Expression and Smoking Intensity to Urothelial Carcinoma of the Bladder Invasiveness: A Cross-Sectional Study.

Pramod SV, Safriadi F, Hernowo BS, Dwiyana RF, Trianasari N, Egawa S. Pramod SV, et al. Among authors: egawa s. Res Rep Urol. 2023 Nov 1;15:485-494. doi: 10.2147/RRU.S433705. eCollection 2023. Res Rep Urol. 2023. PMID: 37933300 Free PMC article.

2

Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).

Yorozu A, Namiki M, Saito S, Egawa S, Yaegashi H, Konaka H, Momma T, Fukagai T, Tanaka N, Ohashi T, Takahashi H, Nakagawa Y, Kikuchi T, Mizokami A, Stone NN. Yorozu A, et al. Among authors: egawa s. Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):390-401. doi: 10.1016/j.ijrobp.2023.08.046. Epub 2023 Oct 4. Int J Radiat Oncol Biol Phys. 2024. PMID: 37802225 Clinical Trial.

3

pT1 Subclassification Predicts Progression-Free Survival in En Bloc Resection of Bladder Tumor Specimens.

Sato S, Yanagisawa T, Miki J, Hayashida Y, Okada Y, Iwatani K, Matsukawa A, Kimura T, Egawa S, Shimoda M, Takahashi H. Sato S, et al. Among authors: egawa s. Arch Pathol Lab Med. 2024 May 1;148(5):573-580. doi: 10.5858/arpa.2023-0044-OA. Arch Pathol Lab Med. 2024. PMID: 37671794 Free article.

4

Osteoblast-derived extracellular vesicles exert osteoblastic and tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer.

Ito K, Yamamoto T, Hayashi Y, Sato S, Nakayama J, Urabe F, Shimasaki T, Nakamura E, Matui Y, Fujimoto H, Kimura T, Egawa S, Ochiya T, Yamamoto Y. Ito K, et al. Among authors: egawa s. Mol Oncol. 2023 Oct;17(10):2147-2167. doi: 10.1002/1878-0261.13484. Epub 2023 Aug 4. Mol Oncol. 2023. PMID: 37408474 Free PMC article.

5

Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein.

Urabe F, Kosaka N, Yamamoto Y, Ito K, Otsuka K, Soekmadji C, Egawa S, Kimura T, Ochiya T. Urabe F, et al. Among authors: egawa s. J Extracell Vesicles. 2023 Mar;12(3):e12312. doi: 10.1002/jev2.12312. J Extracell Vesicles. 2023. PMID: 36880252 Free PMC article.

6

The highest percentage of Gleason Pattern 4 is a predictor in intermediate-risk prostate cancer.

Sato S, Kimura T, Onuma H, Egawa S, Shimoda M, Takahashi H. Sato S, et al. Among authors: egawa s. BJUI Compass. 2022 Oct 17;4(2):234-240. doi: 10.1002/bco2.195. eCollection 2023 Mar. BJUI Compass. 2022. PMID: 36816145 Free PMC article.

7

[A Case of Metastatic Ureteral Cancer Treated with Pembrolizumab without Relapse of Ocular Myasthenia Gravis].

Hara S, Honda M, Kawaharada A, Nakazono M, Onuma H, Yamada H, Kiyota H, Egawa S. Hara S, et al. Among authors: egawa s. Hinyokika Kiyo. 2022 Dec;68(12):377-383. doi: 10.14989/ActaUrolJap_68_12_377. Hinyokika Kiyo. 2022. PMID: 36627771 Free article. Japanese.

8

A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer.

Shiota M, Inoue R, Tashiro K, Kobayashi K, Horiyama S, Kanji H, Eto M, Egawa S, Haginaka J, Matsuyama H. Shiota M, et al. Among authors: egawa s. J Clin Pharmacol. 2023 Apr;63(4):445-454. doi: 10.1002/jcph.2191. Epub 2023 Jan 17. J Clin Pharmacol. 2023. PMID: 36484758 Clinical Trial.

9

Iatrogenic ureteric injury during abdominal or pelvic surgery: a meta-analysis.

Yanagisawa T, Mori K, Quhal F, Kawada T, Mostafaei H, Laukhtina E, Rajwa P, Sari Motlagh R, Aydh A, König F, Pallauf M, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF. Yanagisawa T, et al. Among authors: egawa s. BJU Int. 2023 May;131(5):540-552. doi: 10.1111/bju.15913. Epub 2022 Oct 18. BJU Int. 2023. PMID: 36196670 Review.

10

Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.

Urabe F, Miki K, Kimura T, Sasaki H, Tashiro K, Iwatani K, Matsukawa A, Aikawa K, Tsusumi Y, Morikawa M, Minato K, Sato S, Takahashi H, Aoki M, Egawa S. Urabe F, et al. Among authors: egawa s. Prostate. 2023 Feb;83(2):135-141. doi: 10.1002/pros.24445. Epub 2022 Sep 29. Prostate. 2023. PMID: 36176043

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

362 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Results by year